The Food and Drug Administration (FDA) approved a new medication on Thursday designed to prevent migraines.
The drug, called Aimovig, produced by pharmaceutical giants Amgen and Novartis, is intended to be administered through a monthly injection, and would cost patients $6,900 annually, Amgen said.
The drug blocks a protein fragment called CGRP, which is believed to play a critical role in migraines, the company said. Amgen said that it expects to make the drug available to patients in the U.S. within a week.
Read more at The Hill.